Research ArticleArticle
Open Access
Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study
MASAYOSHI HARIGAI, YOSHIYA TANAKA, SHINGO MAISAWA and the JA21963 Study Group
The Journal of Rheumatology March 2012, 39 (3) 486-495; DOI: https://doi.org/10.3899/jrheum.110994
MASAYOSHI HARIGAI
From the Departments of Pharmacovigilance, and Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, and the Clinical Research Center, Tokyo Medical and Dental University, Tokyo; the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; and Chugai Pharmaceutical Co. Ltd., Tokyo, Japan. M. Harigai, MD, PhD, Departments of Pharmacovigilance, Medicine and Rheumatology, and the Clinical Research Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University; Y. Tanaka, MD, PhD, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; S. Maisawa, BSc, Chugai Pharmaceutical Co. Ltd.
YOSHIYA TANAKA
From the Departments of Pharmacovigilance, and Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, and the Clinical Research Center, Tokyo Medical and Dental University, Tokyo; the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; and Chugai Pharmaceutical Co. Ltd., Tokyo, Japan. M. Harigai, MD, PhD, Departments of Pharmacovigilance, Medicine and Rheumatology, and the Clinical Research Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University; Y. Tanaka, MD, PhD, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; S. Maisawa, BSc, Chugai Pharmaceutical Co. Ltd.
SHINGO MAISAWA
From the Departments of Pharmacovigilance, and Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, and the Clinical Research Center, Tokyo Medical and Dental University, Tokyo; the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; and Chugai Pharmaceutical Co. Ltd., Tokyo, Japan. M. Harigai, MD, PhD, Departments of Pharmacovigilance, Medicine and Rheumatology, and the Clinical Research Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University; Y. Tanaka, MD, PhD, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; S. Maisawa, BSc, Chugai Pharmaceutical Co. Ltd.
From the Departments of Pharmacovigilance, and Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, and the Clinical Research Center, Tokyo Medical and Dental University, Tokyo; the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; and Chugai Pharmaceutical Co. Ltd., Tokyo, Japan. M. Harigai, MD, PhD, Departments of Pharmacovigilance, Medicine and Rheumatology, and the Clinical Research Center, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University; Y. Tanaka, MD, PhD, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; S. Maisawa, BSc, Chugai Pharmaceutical Co. Ltd.
REFERENCES
- 1.↵
- 2.↵
- Takemura S,
- Klimiuk PA,
- Braun A,
- Goronzy JJ,
- Weyand CM
- 3.↵
- 4.↵
- Tighe H,
- Carson D
- 5.↵
- van Zeben D,
- Hazes JM,
- Zwinderman AH,
- Cats A,
- van der Voort EA,
- Breedveld FC
- 6.↵
- 7.↵
- Emery P,
- Fleischmann R,
- Filipowicz-Sosnowska A,
- Schechtman J,
- Szczepanski L,
- Kavanaugh A,
- et al.
- 8.↵
- Cohen SB,
- Emery P,
- Greenwald MW,
- Dougados M,
- Furie RA,
- Genovese MC,
- et al.
- 9.↵
- 10.↵
- 11.↵
- 12.↵
- Genovese MC,
- Kaine JL,
- Lowenstein MB,
- Del Giudice J,
- Baldassare A,
- Schechtman J,
- et al.
- 13.↵
- 14.↵
- 15.↵
- Prevoo ML,
- van ’t Hof MA,
- Kuper HH,
- van Leeuwen MA,
- van de Putte LB,
- van Riel PL
- 16.↵
- van Gestel AM,
- Prevoo ML,
- van ’t Hof MA,
- van Rijswijk MH,
- van de Putte LB,
- van Riel PL
- 17.↵
- 18.↵
- Koike T,
- Harigai M,
- Inokuma S,
- Inoue K,
- Ishiguro N,
- Ryu J,
- et al.
- 19.↵
- Koike T,
- Harigai M,
- Inokuma S,
- Inoue K,
- Ishiguro N,
- Ryu J,
- et al.
- 20.↵
- 21.↵
- 22.↵
- Nishimoto N,
- Hashimoto J,
- Miyasaka N,
- Yamamoto K,
- Kawai S,
- Takeuchi T,
- et al.
- 23.↵
- Nishimoto N,
- Miyasaka N,
- Yamamoto K,
- Kawai S,
- Takeuchi T,
- Azuma J,
- et al.
- 24.↵
- 25.↵
- 26.↵
- Koike T,
- Harigai M,
- Inokuma S,
- Ishiguro N,
- Ryu J,
- Takeuchi T,
- et al.
- 27.↵
In this issue
The Journal of Rheumatology
Vol. 39, Issue 3
1 Mar 2012
Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study
MASAYOSHI HARIGAI, YOSHIYA TANAKA, SHINGO MAISAWA, the JA21963 Study Group
The Journal of Rheumatology Mar 2012, 39 (3) 486-495; DOI: 10.3899/jrheum.110994
Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study
MASAYOSHI HARIGAI, YOSHIYA TANAKA, SHINGO MAISAWA, the JA21963 Study Group
The Journal of Rheumatology Mar 2012, 39 (3) 486-495; DOI: 10.3899/jrheum.110994